Polyrizon (NASDAQ:PLRZ) Cut to “Sell” at Wall Street Zen

Polyrizon (NASDAQ:PLRZ) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Separately, Weiss Ratings lowered shares of Polyrizon from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, May 21st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Polyrizon Trading Up 4.1%

Shares of NASDAQ PLRZ opened at $17.17 on Friday. The firm’s 50-day moving average price is $13.76 and its 200-day moving average price is $12.06. Polyrizon has a 1-year low of $2.88 and a 1-year high of $18.20.

Polyrizon (NASDAQ:PLRZ) last announced its quarterly earnings data on Saturday, February 14th. The company reported ($2.81) earnings per share for the quarter.

Institutional Investors Weigh In On Polyrizon

A hedge fund recently bought a new stake in Polyrizon stock. Jane Street Group LLC bought a new position in shares of Polyrizon Ltd. (NASDAQ:PLRZ) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 14,032 shares of the company’s stock, valued at approximately $119,000. Jane Street Group LLC owned approximately 1.35% of Polyrizon at the end of the most recent reporting period.

About Polyrizon

Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.